- Home
- SOS vs HIND Comparison
SOS vs HIND Comparison
Compare SOS & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | SOS | HIND |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | China | United States |
| Employees | N/A | 2 |
| Industry | Finance: Consumer Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 15.2M |
| IPO Year | 2005 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SOS | HIND |
|---|---|---|
| Price | $0.36 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 2.5M | 14.5K |
| Earning Date | 05-15-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 64.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $319,714.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.43 |
| 52 Week Low | $0.29 | $1.75 |
| 52 Week High | $2.35 | $6.56 |
Technical Indicators
Market Signals| Indicator | SOS | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 26.88 | 46.91 |
| Support Level | N/A | $1.99 |
| Resistance Level | $1.10 | $2.31 |
| Average True Range (ATR) | 0.16 | 0.10 |
| MACD | -0.04 | -0.00 |
| Stochastic Oscillator | 7.95 | 43.06 |
Price Performance
Historical ComparisonAbout SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing and other Hosting services. The company has single reporting segment: Commodity trading and generates key revenue is generated from Commodity trading.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.